Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
0 Years and older, Male and Female
208750 (primary)
NCI-2018-01288
ADP-0000-002
Summary
This trial will evaluate long term safety of participants who have received AdaptImmune
(ADP) adoptive cell therapy for up to 15 years following last adoptive cell therapy
infusion.
Objectives
Participants who received a ADP adoptive cell therapy will be enrolled in this
non-therapeutic, multi-center, long term follow-up (LTFU) study and will be followed for
up to 15 years post-infusion of lentiviral vector-based adoptive cell therapy.
Participants will be monitored for safety following last adoptive cell therapy infusion.
Eligibility
- Participants who have received at least one dose of ADP adoptive cell therapy agent.
- Participants who have completed ADP sponsored or supported interventional study or have withdrawn from it.
- Participants who have completed treatment as part of managed access to a GSK adoptive cell therapy.
- Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
- The investigator is responsible for review of medical history.
- Capable of giving signed informed consent.
Treatment Sites in Georgia
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts...
Click here to learn more about clinical trials.